Rational engineering of antibody therapeutics targeting multiple oncogene pathways

mAbs

Volumn 3, Issue 3, 2011, Pages 299-309

  Fitzgerald, Jonathan ^a   Lugovskoy, Alexey ^a  

^a MERRIMACK PHARMACEUTICALS   (United States)

Author keywords

Antibody; Bispecific; Cancer therapeutics; Design; Simulation; Stability

Indexed keywords

(1 BUTYLAMINO 3 METHYLBUTYL)(1 PYRROLIDINYL) KETONE; ASPARAGINE; BISPECIFIC ANTIBODY; CYSTEINE; DUAL VARIABLE DOMAIN IMMUNOGLOBULIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FC RECEPTOR IIA; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; MEMBRANE ANTIGEN; METHIONINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIBODY ENGINEERING; ANTIGEN BINDING; BINDING AFFINITY; CANCER GROWTH; CELL SELECTION; CELL SURFACE; CYTOTOXICITY; DRUG MECHANISM; DRUG SYNTHESIS; GENE TARGETING; HUMAN; IC 50; ONCOGENE; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; REVIEW; SIGNAL TRANSDUCTION; SIMULATION;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; COMPUTER SIMULATION; DRUG DESIGN; HUMANS; MODELS, IMMUNOLOGICAL; NEOPLASMS; ONCOGENE PROTEINS; PROTEIN ENGINEERING; SIGNAL TRANSDUCTION; SINGLE-CHAIN ANTIBODIES; TECHNOLOGY, PHARMACEUTICAL;

EID: 79955658810     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.3.15299     Document Type: Review

References (83)

1. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs 2009; 1:539-47.
2. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9:767-74.
3. Gossage L, Eisen T. Targeting multiple kinase pathways: a change in paradigm. Clin Cancer Res 2010; 16:1973-8.
4. Chen LF, Cohen EEW, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 2010; 16:2489-95.
5. Huang X, Gao L, Wang S, McManaman JL, Thor AD, Yang X, et al. Heterotrimerization of the growth factor receptors erbB2, erbB3 and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res 2010; 70:1204-14.
6. Browne BC, Crown J, Venkatesan N, Duffy MJ, Clynes M, Slamon D, et al. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol 2011;22:68-73.
7. Cirstea D, Vallet S, Raje N. Future novel single agent and combination therapies. Cancer J 2009; 15:511-8.
8. Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, et al. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 2010;28:4240-6.
9. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27:672-80.
10. Lu D, Zhang H, Koo H, Tonra J, Balderes P, Prewett M, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005;280:19665-72. (Pubitemid 41379490)
11. Baeuerle Pa, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res 2009;69:4941-4.
12. Michaelson JS, Demarest SJ, Miller B, Amatucci A, Snyder WB, Wu X, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR. MAbs 2009;1:128-41.
13. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7. (Pubitemid 350076510)
14. Dower SK, DeLisi C, Titus JA, Segal DM. Mechanism of binding of multivalent immune complexes to Fc receptors. 1. Equilibrium binding. Biochemistry 1981; 20:6326-34.
15. Dower SK, Titus JA, DeLisi C, Segal DM. Mechanism of binding of multivalent immune complexes to Fc receptors. 2. Kinetics of binding. Biochemistry 1981;20:6335-40.
16. Wofsy C, Goldstein B. Cross-linking of Fcgamma receptors and surface antibodies. Theory and application. Journal of immunology (Baltimore, Md 1950) 1990; 145:1814-25.
17. Lippow SM, Wittrup KD, Tidor B. Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol 2007; 25:1171-6. (Pubitemid 47538113)
18. Dong J, Sereno A, Snyder WB, Miller BR, Tamraz S, Doern A, et al. Stable IgG-like bispecific antibodies directed towards the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activity. J Biol Chem 2011; 286:4703-17.
19. Robinson MK, Hodge KM, Horak E, Sundberg a L, Russeva M, Shaller CC, et al. Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br J Cancer 2008; 99:1415-25.
20. Cohen-Solal JFG, Cassard L, Fridman WH, Sautès-Fridman C. Fcgamma receptors. Immunol Lett 2004; 92:199-205.
21. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo J. Immunol 2003; 171:1581-7. (Pubitemid 36900094)
22. Brambell FWR, Hemmings WA, Morris IG. A Theoretical Model of γ-Globulin Catabolism. Nature 1964; 203:1352-5.
23. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6:443-6. (Pubitemid 30208162)
24. Zalevsky J, Chamberlain AK, Horton HM, Karki S, Leung IWL, Sproule TJ, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechol 2010; 28:157-9.
25. Akewanlop C, Watanabe M, Singh B, Walker M, Kufe DW, Hayes DF. Phagocytosis of Breast Cancer Cells Mediated by Anti-MUC-1 Monoclonal Antibody, DF3 and Its Bispecific Antibody. Cancer Res 2001; 61:4061-5. (Pubitemid 32720971)
26. Glockshuber R, Malia M, Pfitzinger I, Plueckthun A. A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 1990; 29:1362-7. (Pubitemid 20063361)
27. Coloma MJ, Morrison SL. Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 1997; 15:159-63. (Pubitemid 27081782)
28. Orcutt KD, Ackerman ME, Cieslewicz M, Quiroz E, Slusarczyk AL, Frangioni JV, et al. A modular IgG-scFv bispecific antibody topology. Protein Eng Des Sel 2010; 23:221-8.
29. Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, et al. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J Mol Biol 2009;393:672-92.
30. Ridgway JB, Presta LG, Carter P. "Knobs-into-holes" engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21.
31. Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, et al. MetMAb, the one-armed 5D5 antic-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008;68:4360-8.
32. Bossenmaier B, Brinkmann U, Klein C, Niederfellner G, Schaefer W, Schanzer JM, et al. Bispecific Anti-ErbB1/Anti-c-Met Antibodies. WO/2010/11555 2010.
33. Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: Applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285:19637-46.
34. Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23:195-202.
35. Bostrom J, Yu SF, Kan D, Appleton Ba, Lee CV, Billeci K, et al. Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site. Science 2009; 323:1610-4.
36. Lipinski C. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46:3-26. (Pubitemid 33653411)
37. Proba K, Honegger A, Plückthun A. A natural antibody missing a cysteine in VH: consequences for thermodynamic stability and folding. J Mol Biol 1997; 265:161-72. (Pubitemid 27110655)
38. Qian J, Liu T, Yang L, Daus A, Crowley R, Zhou Q. Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequential enzymatic digestion. Anal Biochem 2007; 364:8-18. (Pubitemid 46497948)
39. Moore KL. Protein tyrosine sulfation: a critical post-translation modification in plants and animals. Proc Natl Acad Sci USA 2009; 106:14741-2.
40. Wang W, Vlasak J, Li Y, Pristatsky P, Fang Y, Pittman T, et al. Impact of methionine oxidation in human IgG1 Fc on serum half-life of monoclonal antibodies. Mol Immunol 2011; In press.
41. Robinson NE, Robinson AB. Deamidation of human proteins. Proc Natl Acad Sci USA 2001; 98:12409-13. (Pubitemid 33019959)
42. Liu H, Gaza-Bulseco G, Sun J. Characterization of the stability of a fully human monoclonal IgG after prolonged incubation at elevated temperature. J Chromatogr B Analyt Technol Biomed Life Sci 2006;837:35-43. (Pubitemid 43796295)
43. Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, et al. Trends in Glycosylation, Glycoanalysis and Glycoengineering of Therapeutic Antibodies and Fc-Fusion Proteins. Curr Pharm Biotechnol 2008; 9:482-501.
44. Martinez T, Pace D, Brady L, Gerhart M, Balland A. Characterization of a novel modification on IgG2 light chain. Evidence for the presence of O-linked mannosylation. J Chromatogr A 2007; 1156:183-7. (Pubitemid 46935743)
45. Valliere-Douglass JF, Brady LJ, Farnsworth C, Pace D, Balland A, Wallace A, et al. O-fucosylation of an antibody light chain: characterization of a modification occurring on an IgG1 molecule. Glycobiology 2009; 19:144-52.
46. Wagner-Rousset E, Bednarczyk A, Bussat MC, Colas O, Corvaïa N, Schaeffer C, et al. The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872:23-37.
47. Clark La, Boriack-Sjodin PA, Eldredge J, Fitch C, Friedman B, Hanf KJM, et al. Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci 2006; 15:949-60.
48. Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23:549-57.
49. Boder ET, Midelfort KS, Wittrup KD. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc Natl Acad Sci USA 2000; 97:10701-5.
50. Tsurushita N, Hinton PR, Kumar S. Design of humanized antibodies: from anti-Tac to Zenapax. Methods 2005; 36:69-83. (Pubitemid 40558817)
51. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1:457-62. (Pubitemid 37361488)
52. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. The AAPS J 2006; 8:501-7.
53. Kvam E, Sierks MR, Shoemaker CB, Messer A. Physico-chemical determinants of soluble intrabody expression in mammalian cell cytoplasm. Protein Eng Des Sel 2010; 23:489-98.
54. Pepinsky RB, Silvian L, Berkowitz Sa, Farrington G, Lugovskoy A, Walus L, et al. Improving the solubility of anti-LINGO-1 monoclonal antibody Li33 by isotype switching and targeted mutagenesis. Protein Sci 2010; 19:954-66.
55. Chennamsetty N, Helk B, Voynov V, Kayser V, Trout BL. Aggregation-prone motifs in human immunoglobulin G. J Mol Biol 2009; 391:404-13.
56. Voynov V, Chennamsetty N, Kayser V, Helk B, Trout BL. Predictive tools for stabilization of therapeutic proteins. MAbs 2009; 1:580-2.
57. Zhao P, Zhang L, Grillo JA, Liu Q, Bullock JM, Moon YJ, et al. Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review. Clin Pharmacol Ther 2011; 89:259-67.
58. Wolf-Yadlin A, Hautaniemi S, Lauffenburger DA, White FM. Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci USA 2007; 104:5860-5. (Pubitemid 47175624)
59. Chen WW, Schoeberl B, Jasper PJ, Niepel M, Nielsen UB, Lauffenburger DA, et al. Input-output behavior of ErbB signaling pathways as revealed by a mass action model trained against dynamic data. Mol Syst Biol 2009; 5:239.
60. Gaudet S, Janes KA, Albeck JG, Pace EA, Lauffenburger DA, Sorger PK. A compendium of signals and responses triggered by prodeath and prosurvival cytokines. Mol Cell Proteomics 2005; 4:1569-90. (Pubitemid 41555481)
61. Birtwistle MR, Hatakeyama M, Yumoto N, Ogunnaike BA, Hoek JB, Kholodenko BN. Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses. Mol Syst Biol 2007; 3:144.
62. Kiyatkin A, Aksamitiene E, Markevich NI, Borisov NM, Hoek JB, Kholodenko BN. Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by multiple positive feedback loops. J Biol Chem 2006; 281:19925-38. (Pubitemid 44065766)
63. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, et al. Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2009; 2:31.
64. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK. Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2006; 2:458-66. (Pubitemid 44266307)
65. Ross JS. Breast cancer biomarkers and HER2 testing after 10 years of anti-HER2 therapy. Drug News Perspect 2009; 22:93-106.
66. Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 2010; 251:254-60.
67. Hirsch FR, Varella-Garcia M, Bunn PA, Di Maria MV, Veve R, Bremmes RM, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21:3798-807. (Pubitemid 46606235)
68. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7:505-16. (Pubitemid 44036456)
69. Hendriks BS, Wiley HS, Lauffenburger D. HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms. Biophys J 2003; 85:2732-45.
70. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, et al. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation. Cancer Res 2010; 70:2485-94.
71. Riel NAW van. Dynamic modelling and analysis of biochemical networks: mechanism-based models and model-based experiments. Brief Bioinform 2006; 7:364-74.
72. Wörn A, Plückthun A. Stability engineering of antibody single-chain Fv fragments. J Mol Biol 2001; 305:989-1010. (Pubitemid 33028934)
73. Reiter Y, Brinkmann U, Webber KO, Jung SH, Lee B, Pastan I. Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv. Protein Eng Des Sel 1994; 7:697-704. (Pubitemid 24150079)
74. Wörn A, Plückthun A. Mutual stabilization of VL and VH in single-chain antibody fragments, investigated with mutants engineered for stability. Biochemistry 1998; 37:13120-7. (Pubitemid 28449555)
75. Wang N, Smith WF, Miller BR, Aivazian D, Lugovskoy AA, Reff ME, et al. Conserved amino acid networks involved in antibody variable domain interactions. Proteins 2009; 76:99-114.
76. Jung S, Plückthun A. Improving in vivo folding and stability of a single-chain Fv antibody fragment by loop grafting. Protein Eng 1997; 10:959-66. (Pubitemid 27491653)
77. Jordan JL, Arndt JW, Hanf K, Li G, Hall J, Demarest S, et al. Structural understanding of stabilization patterns in engineered bispecific Ig-like antibody molecules. Proteins 2009; 77:832-41.
78. Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 1-9.
79. Jung S, Honegger A, Plückthun A. Selection for improved protein stability by phage display. J Mol Biol 1999; 294:163-80.
80. Shusta EV, Kieke MC, Parke E, Kranz DM, Wittrup KD. Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. J Mol Biol 1999; 292:949-56. (Pubitemid 29481708)
81. Baldi L, Muller N, Picasso S, Jacquet R, Girard P, Thanh HP, et al. Transient gene expression in suspension HEK-293 cells: application to large-scale protein production. Biotechnol Prog 2005; 21:148-53. (Pubitemid 40218483)
82. Lavinder JJ, Hari SB, Sullivan BJ, Magliery TJ. High-throughput thermal scanning: a general, rapid dye-binding thermal shift screen for protein engineering. J Am Chem Soc 2009; 131:3794-5.
83. Miller BR, Glaser SM, Demarest SJ. Rapid screening platform for stabilization of scFvs in Escherichia coli. Methods Mol Biol 2009; 525:279-89.